Answers are grounded in this paper and cite their sources.
Of the roughly 8 million people who will develop tuberculosis this year, only a minority will get a laboratory-supported diagnosis. 1 Global Tuberculosis ControlWHO Report, 2000. WHO, Geneva2000 Google Scholar The insensitivity and laboriousness of sputum microscopy, a test fundamentally unchanged since its introduction in the 19th century, are the biggest obstacles to improving this situation. Inadequate tools for diagnosing tuberculosis also keep other critical subsets of patients from having access to targeted interventions, such as specific therapy for multidrug-resistant disease and treatment of latent infection. Why is the diagnostic armamentarium for one of the world's greatest public-health threats still reliant on antiquated approaches? Desired characteristics of new tests have been spelled out in some detail, 2 Foulds J O'Brien R New tools for the diagnosis of tuberculosis: the perspective of developing countries. Int J Tuberc Lung Dis. 1998; 2: 778-783 PubMed Google Scholar , 3 Meeting Report. WHO Workshop on Tuberculosis Diagnostics, November, 1997. www.who.int/tdr/diseases/tb/pubs.htm (accessed on Sept 14, 2000). Google Scholar and recent advances in molecular biology, immunology, functional genomics, and nanotechniques have given birth to several promising assays. The new generation of candidate skintest reagents described by Peter Andersen and colleagues in this issue of The Lancet is representative of progress in the topic. Why have such research advances not resulted in important changes in the way tuberculosis is detected and managed? Why has there been so little progress in understanding how best to use new assays or what their potential impact might be on control of tuberculosis? A review of published work points the finger at the unsatisfactory design and execution of trials of diagnostic tests. Specific immune-based diagnosis of tuberculosisCurrent diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis. The identification of regions of the M tuberculosis genome that are not present in BCG and non-tuberculous mycobacteria provides a unique opportunity to develop new highly specific diagnostic reagents. We describe the current status of attempts to exploit this information and summarise recent research that has used defined antigens for an accurate and rapid test for tuberculosis infection based on the detection of T cells sensitised to M tuberculosis either by blood tests in vitro or skin tests in vivo.
No takes yet. Share an insight, caveat, or question.
Small et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: